Xilio Therapeutics (XLO) Net Equity Issued and Repurchased (2021 - 2025)

Xilio Therapeutics (XLO) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $2.0 million in Q1 2025.

• For the quarter ending Q1 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (up 107.07% YoY), and the FY2025 full-year result was $2.0 million, down 70.45% from the prior year.
• Net Equity Issued and Repurchased improved to $2.0 million in Q1 2025, from $1000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $144.9 million in Q1 2021 to a low of -$28.5 million in Q4 2021.
• A 3-year average of $29.6 million and a median of $1.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.